New drug cocktail aims to keep ovarian cancer at bay after initial treatment
NCT ID NCT06083844
Summary
This study is testing whether combining three existing drugs—pembrolizumab, bevacizumab, and low-dose cyclophosphamide—can help control high-grade ovarian cancer that is still present in small amounts after a patient's first round of treatment. The goal is to see if this combination can delay the cancer's return. Researchers will also closely monitor the safety of this treatment approach in about 20 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.